{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:33:53Z","timestamp":1758710033910},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"DOI":"10.7759\/cureus.36780","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T07:56:47Z","timestamp":1679990207000},"source":"Crossref","is-referenced-by-count":2,"title":["A Case Report on Serotonin Syndrome in a Patient With Parkinson\u2019s Disease: Diagnostic and Management Challenges"],"prefix":"10.7759","author":[{"given":"Marko","family":"Nemet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Andrijevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0110or\u0111e","family":"Nedeljkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Andri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sr\u0111an","family":"Gavrilovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1178646919873925","article-title":"Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions","volume":"12","author":"Scotton WJ","year":"2019","unstructured":"Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019, 12:10.1177\/1178646919873925","journal-title":"Int J Tryptophan Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204154","article-title":"Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary","volume":"2014","author":"Dosi R","year":"2014","unstructured":"Dosi R, Ambaliya A, Joshi H, Patell R. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep. 2014, 2014:10.1136\/bcr-2014-204154","journal-title":"BMJ Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200007000-00001","article-title":"Serotonin syndrome. Presentation of 2 cases and review of the literature","volume":"79","author":"Mason PJ","year":"2000","unstructured":"Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000, 79:201-209. 10.1097\/00005792-200007000-00001","journal-title":"Medicine (Baltimore)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer EW","year":"2005","unstructured":"Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005, 352:1112-1120. 10.1056\/NEJMra041867","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31821b3aa0","article-title":"Serotonin syndrome due to duloxetine","volume":"34","author":"Gelener P","year":"2011","unstructured":"Gelener P, Gorgulu U, Kutlu G, Ucler S, Inan LE. Serotonin syndrome due to duloxetine. Clin Neuropharmacol. 2011, 34:127-128. 10.1097\/WNF.0b013e31821b3aa0","journal-title":"Clin Neuropharmacol"},{"key":"ref6","article-title":"Interaction between monoamine oxidase b inhibitors and selective serotonin reuptake inhibitors","volume":"71","author":"Aboukarr A","year":"2018","unstructured":"Aboukarr A, Giudice M. Interaction between monoamine oxidase b inhibitors and selective serotonin reuptake inhibitors\r\n. Can J Hosp Pharm. 2018, 71:196-207.","journal-title":"Can J Hosp Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1500","article-title":"Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO)","volume":"34","author":"Panisset M","year":"2014","unstructured":"Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014, 34:1250-1258. 10.1002\/phar.1500","journal-title":"Pharmacotherapy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2009.08.014","article-title":"Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram","volume":"33","author":"Hilli J","year":"2009","unstructured":"Hilli J, Korhonen T, Laine K. Lack of clinically significant interactions between concomitantly administered rasagiline and escitalopram. Prog Neuropsychopharmacol Biol Psychiatry. 2009, 33:1526-1532. 10.1016\/j.pnpbp.2009.08.014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25416","article-title":"Encephalopathy associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome","volume":"28","author":"Duval F","year":"2013","unstructured":"Duval F, Flabeau O, Razafimahefa J, Spampinato U, Tison F. Encephalopathy associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome. Mov Disord. 2013, 28:1464. 10.1002\/mds.25416","journal-title":"Mov Disord"},{"key":"ref10","article-title":"Combination of escitalopram and rasagiline induced serotonin syndrome: a case report and review literature","volume":"98","author":"Suphanklang J","year":"2015","unstructured":"Suphanklang J, Santimaleeworagun W, Supasyndh O. Combination of escitalopram and rasagiline induced serotonin syndrome: a case report and review literature. J Med Assoc Thai. 2015, 98:1254-1257.","journal-title":"J Med Assoc Thai"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2016.10.002","article-title":"Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient","volume":"172","author":"H\u00e9bant B","year":"2016","unstructured":"H\u00e9bant B, Guillaume M, Desbordes M, Gaillon G, Malt\u00eate D, Lefaucheur R. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Rev Neurol (Paris). 2016, 172:788-789. 10.1016\/j.neurol.2016.10.002","journal-title":"Rev Neurol (Paris)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23649","article-title":"Rasagiline-induced serotonin syndrome","volume":"26","author":"Fernandes C","year":"2011","unstructured":"Fernandes C, Reddy P, Kessel B. Rasagiline-induced serotonin syndrome. Mov Disord. 2011, 26:766-767. 10.1002\/mds.23649","journal-title":"Mov Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s1353-8020(02)00123-2","article-title":"Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group","volume":"9","author":"Ikebe S","year":"2003","unstructured":"Ikebe S, Harada T, Hashimoto T, et al.. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003, 9:47-49. 10.1016\/s1353-8020(02)00123-2","journal-title":"Parkinsonism Relat Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s1353-8020(02)00122-0","article-title":"A collaborative study on the malignant syndrome in Parkinson's disease and related disorders","volume":"9","author":"Takubo H","year":"2003","unstructured":"Takubo H, Harada T, Hashimoto T, et al.. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord. 2003, 9:31-41. 10.1016\/s1353-8020(02)00122-0","journal-title":"Parkinsonism Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s1353-8020(02)00125-6","article-title":"Malignant syndrome in Parkinson's disease: concept and review of the literature","volume":"9","author":"Mizuno Y","year":"2003","unstructured":"Mizuno Y, Takubo H, Mizuta E, Kuno S. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord. 2003, 9:3-9. 10.1016\/s1353-8020(02)00125-6","journal-title":"Parkinsonism Relat Disord"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000640","article-title":"A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome","volume":"37","author":"Gurrera RJ","year":"2017","unstructured":"Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2017, 37:67-71. 10.1097\/JCP.0000000000000640","journal-title":"J Clin Psychopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5811\/cpcem.2018.11.39667","article-title":"Emergent treatment of neuroleptic malignant syndrome induced by antipsychotic monotherapy using dantrolene","volume":"3","author":"Ngo V","year":"2019","unstructured":"Ngo V, Guerrero A, Lanum D, Burgett-Moreno M, Fenati G, Barr S, Neeki MM. Emergent treatment of neuroleptic malignant syndrome induced by antipsychotic monotherapy using dantrolene. Clin Pract Cases Emerg Med. 2019, 3:16-23. 10.5811\/cpcem.2018.11.39667","journal-title":"Clin Pract Cases Emerg Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/120209-a-case-report-on-serotonin-syndrome-in-a-patient-with-parkinsons-disease-diagnostic-and-management-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:59:03Z","timestamp":1707508743000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/120209-a-case-report-on-serotonin-syndrome-in-a-patient-with-parkinsons-disease-diagnostic-and-management-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.36780","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}